It has been said that any sufficiently advanced technology is indistinguishable from magic. For the millions of individuals grappling with thinning hair, applying a topical formula like PP405 directly to the scalp might feel very much like casting a spell.
The innovative molecule, developed by California-based Pelage Pharmaceuticals in partnership with the University of California, Los Angeles (UCLA), has demonstrated a unique capability in clinical trials: it can jolt dormant hair follicles back into active production. Rather than simply helping test participants hold on to the hair they already have, the treatment has been shown to encourage the growth of thick, fully pigmented strands in previously bare patches. This differs significantly from the fine, colorless regrowth often associated with existing over-the-counter and prescription treatments.
The key distinction lies in the mechanism of action. PP405 relies on a metabolic approach rather than a hormonal one. By forcing follicular stem cells to break down glucose, the treatment naturally pushes the hair cycle back into its active growth phase. Pelage has positioned the drug as a science-driven solution designed to work universally. From the outset of its clinical trials, the company intentionally recruited a diverse cohort of women and men representing various skin tones and hair types—an inclusive methodology that has not always been standard practice in dermatological research. The promising results have translated to substantial financial backing, with Pelage raising more than $150 million in venture funding since it began publishing its clinical data in 2024.
This development is part of a broader wave of research and development aiming to transform how society approaches hair loss, potentially saving some patients a long-haul flight to Istanbul, which has established itself as a leading global hub for surgical hair transplants. Other companies are advancing distinct pipelines. Eirion Therapeutics has developed ET-02, another topically applied molecule designed not only to stimulate hair regrowth but also to address the gradual graying of hair. Meanwhile, Veradermics has introduced VDPHL01, an extended-release oral formulation of minoxidil engineered specifically to mitigate the cardiovascular risks that can occasionally accompany traditional blood pressure and hair-loss medications of that class.
Despite these scientific strides, it will likely be years before any of these next-generation therapies clear regulatory hurdles and become available at a standard pharmacy or specialized clinic. The U.S. Food and Drug Administration (FDA) has not approved an entirely new class of hair-loss drug in nearly three decades. And despite the wave of optimistic headlines circulating through the media, plastic surgeons and hair restoration specialists report that their practices are busier than ever.
Data from the International Society of Hair Restoration Surgery (ISHRS) 2025 census underscores this sustained demand, revealing that the average member’s patient load has increased by 20 percent since 2021. Furthermore, the demographic profile of these patients is shifting younger. Approximately 95 percent of individuals seeking professional medical help for hair thinning and baldness now initiate treatment between the ages of 20 and 35.
Dr. Gary Linkov, founder of City Facial Plastics in New York City, categorizes the current hair restoration market into three distinct pillars: stimulation, prevention, and augmentation. He notes that molecules like PP405 and its competitors are crowding the stimulation category, a sector he views as already robustly served.
"I don’t think it’s going to stimulate beyond what we’re stimulating with minoxidil, because [that] already stimulates so well," Dr. Linkov observes.
He adds that the patients filling his waiting room are rarely driven by anticipation of new laboratory breakthroughs. Instead, his practice frequently treats clients returning for revision procedures after bargain-priced surgical interventions abroad resulted in complications, alongside a growing number of women opting for hair transplants. Even futuristic prospects, such as lab-grown hair cloning—which remains years away from comprehensive clinical trials—would not eliminate the need for surgical expertise, as medical professionals would still be required to manually implant the cloned follicles.
Dr. Ross Kopelman, a prominent hair-transplant specialist who has built a substantial audience of nearly 100,000 followers on YouTube, attributes a significant portion of the market’s expansion to the rise of telehealth platforms like Hims and Roman. He suggests that these digital health companies have successfully normalized conversations surrounding hair loss in a manner comparable to how medications like Ozempic shifted public dialogue around weight management.
"It’s almost a rite of passage to say, ‘Hey, I’m taking care of my hair as well,’" Dr. Kopelman remarks.
Like Dr. Linkov, he remains cautious regarding the immediate efficacy of emerging pharmacological treatments. "If you’re bald, you’re bald," he adds, emphasizing that topical agents alone are often insufficient to reverse advanced scarring alopecia or complete follicular death. "It’s not going to regrow hair."
However, alternative therapies are beginning to offer a middle ground between topical maintenance and invasive surgery. Among them is Dezawa MuseCells, a Japanese stem-cell therapy that made its way to the United States this year. Discovered in 2010 by Dr. Mari Dezawa, a professor at Tohoku University in Japan, the therapy is guided in the U.S. market by CEO Dr. Dominik Duscher, a plastic surgeon by training. Dr. Duscher carefully frames the treatment as a complementary companion to a traditional hair transplant rather than a complete substitute.
"Hair transplants make total sense when you have patches of scalp where there’s no hair follicle at all," Dr. Duscher explains. "But you need to flank it with [effective medication]."
For consumers navigating the expanding marketplace, the most reliable approach remains consistent with historical advice: consult a qualified medical professional first and maintain a healthy skepticism toward any brand promising guaranteed results ahead of formal FDA approval. While the traditional hair transplant is far from obsolete, it is increasingly being supported by an array of sophisticated medical and topical sidekicks.
Hair Raiser
The name on Sisley’s newly released bottle is undeniably extensive—requiring deliberate focus to say "Revitalizing Fortifying Super Serum Advanced Formula" multiple times in quick succession—but the branding reflects a substantial investment in research and development. Contained within the sleek glass vial is the successor to the French luxury brand’s award-winning hair tonic, enhanced by recent scientific insights into how the scalp’s natural microbiome influences hair vitality and strength.
The updated formula incorporates ginger extract and vitamin B12 to soothe the skin of the scalp, alongside plant-derived peptides designed to give hair a visibly thicker appearance over time. Consistent use may also help slow the natural graying process.
